Walter M. Stadler

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.

C. Shapiro, J. Sosman, T. Kuzel, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

E. Vokes, R. Amato, W. Stadler, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

M. Ratain, J. Holmlund, G. Fleming, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

K. Griffith, S. Schuetze, W. Stadler, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program

Brittany A. Borden, M. Ratain, R. Nanda, 2017, Clinical pharmacology and therapeutics.

Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma.

T. Zimmerman, B. Rini, W. Stadler, 2001, The Journal of urology.

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.

R. Schilsky, M. Ratain, W. Stadler, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.

M. Ratain, J. Ramírez, G. Fleming, 2011, European Journal of Cancer.